The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction

European Heart Journal

Volumn 28, Issue 4, 2007, Pages 415-424

  Mehta, Rajendra H ^a   Califf, Robert M ^a   Garg, Jyotsna ^a   White, Harvey D ^b   Van De Werf, Frans ^c   Armstrong, Paul W ^d   Pieper, Karen S ^a   Topol, Eric J ^e   Granger, Christopher B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Acute myocardial infarction; Outcomes; Reperfusion; Weight

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; CARDIOGENIC SHOCK; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; STROKE;

BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 34547679023     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl329     Document Type: Article

References (32)

1. Paffenbarger RS, Wolf PA, Notkin J, Thorne MC. Chronic disease in formal college students: early precursors of fatal coronary heart disease. Am J Epidemiol 1966;83:314-328.
2. Palmer JR, Rosenberg L, Shapiro S. Stature and risk of myocardial infarction in women. Am J Epidemiol 1990;132:27-32.
3. Hebert PR, Rich-Edwards JW, Manson JE, Ridker PM, Cook NR, O'Connor GT, Buring JE, Hennekens CH. Height and incidence of cardiovascular disease in male physicians. Circulation 1993;88:1437-1443.
4. Walker M, Sharp AG, Phillips AN, Cook DG. Short stature, lung function and risk of a heart attack. Int J Epidemiol 1989;67:968-977.
5. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in Framingham Heart Study. Circulation 1983;67:968- 977.
6. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998;97:2099-2100.
7. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995;333:677-685.
8. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-1105.
9. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530-1538.
10. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995;91:1659-1668.
11. Mehta RH, Califf RM, Garg J, Pieper KS, Alexander JH, Moliterno DJ, Van der Werf F, Ohman EM, White H, Topol EJ, Granger CB. Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. Am J Cardiol 2005;95:1371-1375.
12. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes in patients undergoing coronary revascularization: Insights from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2002;39:834-840.
13. Califf RM, Pieper KS, Lee KL, Van de Werf F, Simes RJ, Armstrong PW, Topol EJ. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000;101:2231-2238.
14. Mehta RH, ONeill W, Harjai KJ, Boura J, Fox DA, Brodie BR, Stone GW, Grines CL. Predictors of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol 2006;97:817- 822.
15. Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA. Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. Circulation 1999;99:2986-2992.
16. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993;342:1523-1528.
17. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802-1811.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
19. The GUSTO II Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
20. GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
21. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
22. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-613.
23. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with low-molecular-weight heparin enoxapain or unfractionated heparin in pre-hospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Plus randomized trial in acute myocardial infarction. Circulation 2003;108:135-142.
24. The HERO-2 trial investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolysis for acute myocardial infarction. The HERO-2 randomized trial. Lancet 2002;358:1855-1863.
25. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, Bates ER, Vahanian A, Armstrong PW, Criger DA, Topol EJ, Holmes DR. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000;35:136-145.
26. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM, for the Global Utilization of Streptokinase Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators. Incidence and predictors of bleeding following contemporary thrombolytic therapy for myocardial infarction. Circulation 1997;95:2508-2516.
27. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ. Stroke after thrombolytic therapy: mortality and functional outcomes in the GUSTO-I trial. Circulation 1995;92:2811-2818.
28. Schafer JL. Multiple imputation: a primer. Stat Meth Med Res 1999;8:3-15.
29. Gruberg L, Mercado N, Milo S, Boersma E, Disco C, van Es GA, Lemos PA, Ben Tzvi M, Wijns W, Unger F, Beyar R, Serruys PW. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: the Obesity Paradox II? Am J Cardiol 2005;95:439-444.
30. Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (Results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). Am J Cardiol 2004;94:279-283.
31. Antman E, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 Guidelines for Management of Acute Myocardial Infarction). 2004. www.acc.org/clinical/guidelines/stemi/index.pdf.
32. Dagenais GR, Qilong Y, Mann JFE, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60.